Cadila Healthcare - R&D On Track For Covid Vaccine, Niche Product Development: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Cadila Healthcare Ltd. a fully integrated, global healthcare provider has strong capabilities across the pharma value chain- from formulations to active pharmaceutical ingredients and animal healthcare products to wellness products.
The company posted 9% YoY growth in the domestic formulation segment in FY21, with strong growth (15% YoY) in Q4, led by the specialty cluster of products which grew faster than the mass cluster.
In addition, we expect the Covid-19 portfolio to aid further growth in the domestic formulation segment.
It has already launched products like Remdesivir, Hydroxychloroquines, and Pegylated interferon used for treating patients detected with Covid-19
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.